Annual Changes to the NASDAQ Biotechnology Index NEW YORK,

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Annual Changes to the NASDAQ Biotechnology Index

NEW YORK, Dec. 15, 2014 (GLOBE NEWSWIRE) -- The NASDAQ OMX Group, Inc. (Nasdaq: NDAQ ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq: NBI ), which will become effective prior to market open on Monday, December 22, 2014.

The following 44 securities will be added to the Index: Avalanche Biotechnologies, Inc. (Nasdaq: AAVL ), Aerie Pharmaceuticals, Inc. (Nasdaq: AERI ), Akebia Therapeutics, Inc. (Nasdaq: AKBA ), Alder BioPharmaceuticals (Nasdaq: ALDR ), Alimera Sciences Inc. (Nasdaq: ALIM ), Amphastar Pharmaceuticals, Inc. (Nasdaq: AMPH ), ANI Pharmaceuticals, Inc. (Nasdaq: ANIP ), Auspex Pharmaceuticals, Inc. (Nasdaq: ASPX ), Cara Therapeutics, Inc. (Nasdaq: CARA ), Compugen Ltd. (Nasdaq: CGEN ), Celladon Corporation (Nasdaq: CLDN ), Concert Pharmaceuticals, Inc. (Nasdaq: CNCE ), Enanta Pharmaceuticals Inc. (Nasdaq: ENTA ), Flamel Technologies S.A. (Nasdaq: FLML ), Foundation Medicine, Inc. (Nasdaq: FMI ), Amicus Therapeutics, Inc. (Nasdaq: FOLD ), Five Prime Therapeutics (Nasdaq: FPRX ), GW Pharmaceuticals Plc (Nasdaq: GWPH ), Hyperion Therapeutics, Inc. (Nasdaq: HPTX ), Intercept Pharmaceuticals Inc. (Nasdaq: ICPT ), Inovio Pharmaceuticals, Inc. (Nasdaq: INO ), Insmed Inc. (Nasdaq: INSM ), Kite Pharma, Inc. (Nasdaq: KITE ), Karyopharm Therapeutics Inc. (Nasdaq: KPTI ), MacroGenics, Inc. (Nasdaq: MGNX ), Ophthotech Corporation (Nasdaq: OPHT ), Pharmacyclics Inc. (Nasdaq: PCYC ), Aratana Therapeutics, Inc. (Nasdaq: PETX ), POZEN Inc. (Nasdaq: POZN ), Pernix Therapeutics Holdings, Inc. (Nasdaq: PTX ), QLT Inc. (Nasdaq: QLTI ), Ultragenyx Pharmaceutical Inc. (Nasdaq: RARE ), Receptos, Inc. (Nasdaq: RCPT ), Radius Health, Inc. (Nasdaq: RDUS ), Relypsa, Inc. (Nasdaq: RLYP ), Retrophin, Inc. (Nasdaq: RTRX ), Revance Therapeutics, Inc. (Nasdaq: RVNC ), Sage Therapeutics, Inc. (Nasdaq: SAGE ), Theravance Biopharma, Inc. (Nasdaq: TBPH ), Tetraphase Pharmaceuticals, Inc. (Nasdaq: TTPH ), Versartis, Inc. (Nasdaq: VSAR ), Acceleron Pharma Inc. (Nasdaq: XLRN ), Zafgen Inc. (Nasdaq: ZFGN ) and ZS Pharma, Inc. (Nasdaq: ZSPH ).

The Index is designed to track the performance of a set of securities listed on The NASDAQ Stock Market® (NASDAQ®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB).

As a result of the re-ranking, the following eight securities will be removed from the Index: Amarin Corporation PLC (Nasdaq: AMRN ), Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL ), Curis, Inc. (Nasdaq: CRIS ), Esperion Therapeutics, Inc. (Nasdaq: EXPR ), Cellular Dynamics International (Nasdaq: ICEL ), Onconova Therapeutics Inc. (Nasdaq: ONTX ), Rigel Pharmaceuticals Inc. (Nasdaq: RIGL ), and Zogenix, Inc. (Nasdaq: ZGNX ).

About Nasdaq Global Indexes

Nasdaq Global Indexes has been creating innovative, market-leading, transparent indexes since 1971. Today, our index offering spans geographies and asset classes and includes diverse families such as the Dividend Achievers, Global, Nordic, Green Economy, Sharia and Commodity Indexes. We continuously offer new opportunities for financial product sponsors across a wide-spectrum of investable products and for asset managers to measure risk and performance. Nasdaq Global Indexes also provides custom index services and design solutions to selected financial organizations. For more information about Nasdaq Global Indexes, visit indexes.nasdaqomx.com .

Daily index values, weightings and historical data for Nasdaq indexes are available via Nasdaq Global Index Watch and Nasdaq Global Index Data Service .

About Nasdaq

Nasdaq (Nasdaq: NDAQ ) is a leading provider of trading, exchange technology, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,500 listed companies with a market value of over $8.8 trillion and more than 10,000 corporate clients. To learn more, visit www.nasdaq.com/ambition or business.nasdaq.com

The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular financial product or an overall investment strategy. Neither The NASDAQ OMX Group, Inc. nor any of its affiliates makes any recommendation to buy or sell any financial product or any representation about the financial condition of any company or fund. Statements regarding Nasdaq's proprietary indexes are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.

NDAQG

Media Contacts: Joseph Christinat, Nasdaq +1.646.441.5121 Josh Machiz, Nasdaq +1.212.231.5614 Issuer & Investor Contact: Natasha Selzer, Nasdaq +1.301.978.8623

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CMC Declares Dividend Amid Complex Outlook

Updated Category News Views 18

Dividend's Not Just a Regular Check October 13, 2026, marks yet another dividend declaration by CMC. This time, they're dishing out $0.20 per share—a steady payday for loyal shareholders. That's 248 times in a row they've done this song and dance. Odds are, folks holding NYSE:CMC shares are giving the nod of approval, but it ain't just about cash; it's about stability...

Continue Reading
Skiptown Expands in Georgia Amid Growing Demand

Updated Category News Views 19

With the pet care industry barking up a storm lately, Skiptown is ramping up efforts to expand its presence in Georgia. The tech-enabled dog care franchise already has a paw print in Atlanta, but it's sniffing out new opportunities across the state. Now they're on the hunt for franchise owners who can bring this modern approach to more communities. Why Georgia? The Growth...

Continue Reading
New Data on SKYRIZI Offers Hope for Crohn's Patients

Updated Category News Views 13

Treating Crohn's: New Hope on the Horizon Folks, let me tell you, the landscape for treating Crohn's disease just got a bit more interesting. AbbVie's Phase 3 AFFIRM study has brought some attention-grabbing data on the table, showcasing the potential of their drug, SKYRIZI® (risankizumab-rzaa). This ain't just another run-of-the-mill study; these results could be a...

Continue Reading
AtWork Welcomes Franchise Vet Sarah Goehring

Updated Category News Views 18

A Strategic Move for AtWork There's a new heavyweight at AtWork, a name that's been catching attention in the franchise biz lately—Sarah Goehring. This isn't just another appointment; it's a signal flare for AtWork's ambitions. With Goehring, they're doubling down on scaling their operation and drawing in more franchise players who are ready to hit the ground running....

Continue Reading
Home Buying: Unmasking All the Real Budget Costs

Updated Category News Views 10

Home Buying: More Costs Than Meets the Eye Let's face it, buying a home is no stroll in the park. It's a tangled web of numbers and surprises that can leave even the savviest buyer in a daze. Thank goodness for articles like the one from HelloNation featuring Serena LoPiccolo-Smith, which make the invisible visible when it comes to the financial intricacies of home...

Continue Reading
Paradigm Therapeutics: A Beacon in Rare Diseases

Updated Category News Views 4

A Step Towards Recognition You know the old saying: innovation never sleeps. Well, Paradigm Therapeutics seems to have taken that to heart. The company's embarked on a peculiar yet promising journey with SD-101 (Zorblesia™), and here they are, basking in the glow of another nomination for the 2026 Prix Galien USA "Best Start-Up" award. It’s their second shot at this...

Continue Reading
Special Needs Group Partners with MAST to Enhance Accessibility

Updated Category News Views 21

Accessible Travel Takes the Spotlight Ah, the travel biz—just when you think you’ve got it all figured out, along comes a partnership like this to shake things up. Special Needs Group, the big cheese in mobility and medical equipment rentals, is teaming up with MAST Travel Network. Together, they're rolling out initiatives to make the world a bit more accessible, even...

Continue Reading
Simple Home Upgrades That Boost Value Fast

Updated Category News Views 6

Transform Your Home's Curb Appeal Without Breaking The Bank Every homeowner knows that feeling when you look at your house one day and think, "This could use a little something." Say you're strolling through a neighborhood in Fulton, N.Y., and notice a gem. It's not a brand new build, but it gleams with character. You bet it's had a few smart touches that could apply...

Continue Reading
OmniActive's Fenavari: A New Era in Women's Health

Updated Category News Views 32

Pioneering Women's Health with Fenavari You ever wonder why some health products get all the hype? Here's one for the book: OmniActive Health Technologies launching Fenavari, their top-tier contender in the women's health market. Now, we're not talking your run-of-the-mill supplement here. We're stepping onto a new playing field, especially with Dr. Taz Bhatia stepping...

Continue Reading
Trial for Former OB/GYN Arthur Park Begins in Bakersfield

Updated Category News Views 6

A Somber Day for Justice in Bakersfield There’s a buzz in the air, thick with anticipation and grief, as a trial seven years in the making kicks off in Bakersfield. It’s a significant affair, marking a turning point in a saga that’s shadowed the region with untold grief and unresolved accountability. We’re talking about the trial of Arthur Park, a former OB/GYN,...

Continue Reading

Top 5 Most Recently Viewed Articles

WiMi Hologram Cloud's Blockchain-Driven Cloud Service Innovation

Updated Category News Views 140

WiMi Hologram Cloud's Blockchain-Driven Service Innovation WiMi Hologram Cloud Inc. (NASDAQ: WiMi), a premier global provider of Hologram Augmented Reality (AR) Technology, has unveiled a transformative Cloud Service Trust Interaction Framework leveraging Blockchain Technology. This innovative framework is designed to improve service credibility while optimizing user...

Continue Reading
Delicious Bagel Chips Now Available Online from Eccentric Bagel

Updated Category News Views 227

Welcome to Eccentric Bagel's Online Shop Prepare to treat yourself to something special from The Eccentric Bagel, where our innovative flavor creations are now available online for everyone to enjoy. We’re excited to introduce our online store, giving you easy access to our one-of-a-kind bagel chips, which can be shipped to customers all over the country. This is a...

Continue Reading
Understanding Hut 8 Corp's Market Dynamics and Trends

Updated Category News Views 165

Insights into Hut 8 Corp's Market Support Hut 8 Corp (NYSE:HUT) has recently seen notable changes in its short interest, raising questions about its market support. The short interest, representing shares sold short, has grown by 5.45% since the latest report. Currently, there are approximately 17.39 million shares sold short, which constitutes around 17.8% of all shares...

Continue Reading
ViCentra Introduces Smartphone-Controlled Diabetes Solution by 2026

Updated Category News Views 213

ViCentra's Upcoming Smartphone-Based Therapy for Diabetes ViCentra, renowned for its innovative Kaleido insulin patch pump, is set to revolutionize diabetes management with the upcoming launch of its smartphone-controlled closed loop therapy. The exciting development is expected to debut in early 2026, promising a more user-friendly approach to insulin delivery and...

Continue Reading
Short Interest Trends and Market Sentiment for Linde PLC

Updated Category News Views 111

Understanding Short Interest for Linde PLC Linde PLC (NYSE: LIN) has shown notable shifts in its short interest recently. The short percent of float for Linde has decreased by 4.59%, indicating fresh dynamics in how traders perceive this leading industrial gas company. Current reports show that there are approximately 4.90 million shares sold short, which represents 1.04%...

Continue Reading